

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT

SIHUAN PHARMACEUTICAL REACHED EXCLUSIVE DISTRIBUTION AGREEMENT IN RELATION TO CARTIZOL, AN INTRA-ARTICULAR INJECTION USING COLLAGEN, WITH CELLONTECH KOREA

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group has recently reached an exclusive distribution agreement in relation to CartiZol (the “**Product**”), an intra-articular injection using collagen, with Cellontech Co., Ltd. from South Korea (“**Cellontech Korea**”), and obtained the exclusive distribution rights for the Product in Chinese mainland.

CartiZol is the first “intra-articular injection using collagen” approved in South Korea, which not only protects and strengthens joints by forming a coating on the perichondrium of human cartilage and peripheral tissues in the joints, but also lubricates the joints, absorbs shocks, reduces friction, and improves visco-elasticity, and replenishes and coats the damaged cartilage tissues. In addition, it can supplement and coat the damaged joint cartilage tissues to assist the natural healing process. The Product can effectively reduce the symptoms of joint swelling and pain, help repair damaged joints and inhibit inflammation.

Osteoarthritis is prevalent in China, with more than 100 million people suffering from the disease. In addition to basic treatment, surgery and medication, intra-articular injections marketed in China mainly include hyaluronic acid, glucocorticoids, medical chitosan, platelet-rich plasma and growth factors. As there is no intra-articular injection using collagen approved or under approval in China, the Product has great potential in the osteoarthritis market in China in the future.

Previously, the Group has reached an exclusive distribution agreement with Cellontech Korea on porcine collagen medical aesthetic filler products in 2023, and obtained the exclusive distribution right in Chinese mainland. Cellontech Korea is the earliest manufacturer of porcine collagen raw materials in South Korea, with FDA and European approvals. Due to its unique production technology, the porcine collagen of Cellontech Korea is a de-immunogenic collagen, which is therefore the safest and most cost-effective collagen product.

Cellontech Korea is founded in 2000, since then, by leveraging the essential factors of ‘cells’ and ‘biomaterials’ that constitute human tissues, it has focused its R&D efforts on regenerative therapies, aesthetic treatments, blood and immune disorder treatments, in areas such as bone joints, cartilage, bones, connective tissues (ligaments-tendons), and skin. It has successfully commercialized a wide range of advanced regenerative medical products centered around independently developed BioCollagen materials.

About Sihuan Pharmaceutical

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group’s latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 6 August 2024

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.